Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China
· Delayed Price · Currency is CNY 14.12
+0.05 (0.36%)
Mar 10, 2026, 11:29 AM CST
SHA:600535 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | 955.59 | 1,071 | -264.24 | 2,359 | Upgrade
|
| Depreciation & Amortization | - | 484.02 | 504.91 | 517.95 | 487.77 | Upgrade
|
| Other Amortization | - | 18.48 | 11.23 | 14.73 | 15.23 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -2.11 | -0.15 | -1.48 | -44.22 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 218.01 | 1.78 | 352.26 | 265.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | 198.5 | 270.75 | 1,158 | -1,682 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 0.62 | 8.19 | -1.34 | -5.35 | Upgrade
|
| Other Operating Activities | - | -73.79 | -2.03 | -31.24 | 123.82 | Upgrade
|
| Change in Accounts Receivable | - | 78.22 | 1,243 | 535.51 | 1,231 | Upgrade
|
| Change in Inventory | - | 18.32 | -220.72 | -2.86 | -198.37 | Upgrade
|
| Change in Accounts Payable | - | 121.58 | -395.35 | 36.56 | 243.78 | Upgrade
|
| Change in Other Net Operating Assets | - | - | 67.76 | 11.01 | 3.44 | Upgrade
|
| Operating Cash Flow | - | 2,015 | 2,576 | 2,280 | 2,801 | Upgrade
|
| Operating Cash Flow Growth | - | -21.78% | 12.98% | -18.62% | 56.39% | Upgrade
|
| Capital Expenditures | - | -564.94 | -668.82 | -404.41 | -571.73 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 27.58 | 1.19 | 1.34 | 68.92 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -147.31 | Upgrade
|
| Divestitures | - | - | - | - | 424.19 | Upgrade
|
| Investment in Securities | - | -287.57 | -134.14 | -919.91 | 126.42 | Upgrade
|
| Other Investing Activities | - | -115.99 | -1,307 | 56.75 | 56.76 | Upgrade
|
| Investing Cash Flow | - | -940.87 | -2,109 | -1,266 | -42.83 | Upgrade
|
| Short-Term Debt Issued | - | 1,052 | 213.91 | 102.79 | 1 | Upgrade
|
| Long-Term Debt Issued | - | 1,451 | 1,817 | 2,711 | 1,441 | Upgrade
|
| Total Debt Issued | - | 2,504 | 2,031 | 2,814 | 1,442 | Upgrade
|
| Short-Term Debt Repaid | - | -1,132 | -127 | -9.87 | -82.14 | Upgrade
|
| Long-Term Debt Repaid | - | -2,597 | -1,345 | -2,311 | -2,717 | Upgrade
|
| Total Debt Repaid | - | -3,729 | -1,472 | -2,321 | -2,799 | Upgrade
|
| Net Debt Issued (Repaid) | - | -1,225 | 559.55 | 492.71 | -1,358 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -60.8 | -56.43 | Upgrade
|
| Common Dividends Paid | - | -1,042 | -563.22 | -553.97 | -610.49 | Upgrade
|
| Other Financing Activities | - | -186.05 | -1,193 | -114.58 | -458.73 | Upgrade
|
| Financing Cash Flow | - | -2,454 | -1,196 | -236.63 | -2,483 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 0.16 | -1.26 | 30.39 | 1.94 | Upgrade
|
| Net Cash Flow | - | -1,380 | -730.54 | 807.36 | 276.97 | Upgrade
|
| Free Cash Flow | - | 1,450 | 1,907 | 1,875 | 2,229 | Upgrade
|
| Free Cash Flow Growth | - | -23.98% | 1.68% | -15.89% | 61.28% | Upgrade
|
| Free Cash Flow Margin | - | 17.06% | 21.98% | 21.71% | 28.04% | Upgrade
|
| Free Cash Flow Per Share | - | 0.97 | 1.28 | 1.28 | 1.48 | Upgrade
|
| Cash Interest Paid | - | 8.41 | - | 4.05 | - | Upgrade
|
| Cash Income Tax Paid | - | 993.38 | 1,099 | 1,106 | 1,008 | Upgrade
|
| Levered Free Cash Flow | - | 956.26 | 1,348 | 1,517 | 2,531 | Upgrade
|
| Unlevered Free Cash Flow | - | 994.56 | 1,400 | 1,557 | 2,580 | Upgrade
|
| Change in Working Capital | - | 215.24 | 709.88 | 535.21 | 1,281 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.